In November 2004, the FDA issued a final rule requiring HCT/P establishments to operate in accordance with Current Good Tissue Practice (CGTP) for the collection, donor screening, donor testing, processing, storage, labeling, packaging and distribution of HCT/Ps to prevent the introduction, transmission and spread of communicable diseases. The core CGTP requirements cover facilities, environmental controls, equipment, supplies and reagents, recovery, processing and processing controls, labeling controls, storage, and distribution (including receipt and predistribution shipment). The regulations for CGTPs are found in 21 CFR 1271 Subpart D; FDA recommendations for compliance with the regulations also are available.
FDA to Host Virtual Town Hall on Gene Therapy Manufacturing
September 11, 2025
CMS to Join AABB eCast on Cellular Therapies Coding and Reimbursement
September 10, 2025
AABB Case Study Highlights CABP Credential’s Impact Across Biotherapies
September 10, 2025